Sign in
4

Changes in Ownership

BioXcel Therapeutics, Inc. Filed Acc 0001104659-24-100751

CEO and President sold 1,982 shares at an average $0.69 ($1,367)

  • CEO and President acquired 6,109 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Mehta Vimal · CEO and President

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2024-09-14 Exercise or conversion : show line 1 in the form 10b5-1 +2,609 50,148 D
2024-09-15 Exercise or conversion : show line 2 in the form 10b5-1 +3,500 53,648 D
2024-09-16 Sale : show line 3 in the form 10b5-1 −832 $0.69 $573 52,816 D
2024-09-16 Sale : show line 4 in the form 10b5-1 −1,150 $0.69 $794 51,666 D
Open-market sales · 1,982 sh · avg $0.69 · $1,367

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2024-09-14 Exercise or conversion : show line 5 in the form 10b5-1 Restricted Stock Units −2,609 15,657 D
2024-09-15 Exercise or conversion : show line 6 in the form 10b5-1 Restricted Stock Units −3,500 35,000 D
Loading xslF345X05/tm2424255-6_4seq1.xml…